About Us | Contact Us |        

The Eyes Have It: Optimizing the Treatment of AMD and DME (Enduring)

1.5 AMA PRA Category 1 Credit(s)
Launch Date:
January 03, 2014
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

Ophthalmologists, Retinal Specialists

Relevant Terms:

Diabetic Macular Edema, Age-Related Macular Degeneration

David S. Boyer, MD

David S. Boyer, MD
Retinal-Vitreous Associates Medical Group
Los Angeles, CA

David Boyer, MD, is a partner with Retinal-Vitreous Associates Medical Group in Los Angeles and Clinical Associate Professor at the University of Southern California. After graduating from the Chicago Medical School, he completed his ophthalmology residency at USC County Medical Center in Los Angeles and a fellowship at Wills Eye Hospital in Philadelphia. Dr. Boyer is a past recipient of the Jules Stein Living Tribute award and the Honor Award from the American Academy of Ophthalmology Board of Trustees. Over the past three decades, Dr. Boyer has presented numerous abstracts and invited lectures at various national and international symposia. He has authored a number of scientific papers and a medical text chapter, and is currently an investigator for several clinical trials.

Jeffery S. Heier, MD

Jeffery S. Heier, MD
Director, Vitreoretinal Service
Ophthalmic Consultants of Boston
Boston, MA

Jeffrey S. Heier, MD, is a Vitreoretinal Specialist at Ophthalmic Consultants of Boston, Co-Director of the Vitreoretinal Fellowship at OCB/Tufts Medical School, and President of the Center for Eye Research and Education in Boston, Massachusetts. Dr. Heier's academic appointments include an instructorship in ophthalmology at Tufts University School of Medicine and Harvard University Medical School, both in Boston. 

Dr. Heier received a medical degree from Boston University School of Medicine in Massachusetts, and subsequently completed a transitional internship, ophthalmic residency, and vitreoretinal fellowship at Fitzsimons Army Medical Center. Additional postgraduate training includes a vitreoretinal fellowship completed at Ophthalmic Consultants of Boston/Tufts University School of Medicine. 

Dr. Heier's research interests are focused on age-related macular degeneration (ARMD), diabetic retinopathy, and innovation in vitreoretinal surgical instrumentation: areas he has pursued as lead or principal investigator in numerous clinical trials. Specifically, he has examined prophylaxis and treatment of exudative ARMD; prophylaxis and treatment of cystoid macular edema following cataract and retinal detachment surgery; innovative treatments of diabetic retinopathy (both pharmacologic and surgical); and evaluation of 25-gauge vitrectomy. Dr. Heier presents his research findings at conferences worldwide in addition to contributing to the medical literature. His work has appeared in such journals as Archives of Ophthalmology, American Journal of Ophthalmology, and Ophthalmology.

Michael S. Ip, MD

Michael S. Ip, MD
Associate Professor
University of Wisconsin
Department of Ophthalmology and Visual Sciences
Madison, WI

Michael S. Ip, MD, is Associate Professor, Department of Ophthalmology and Visual Sciences, and Co-Director of the Fundus Photograph Reading Center at the University of Wisconsin Medical School in Madison. He serves as Director of Retina Service at William S. Middleton Memorial Veterans Hospital in Madison. He also has an active clinical practice as a vitreoretinal surgeon that concentrates on the surgical management of retinal detachment and other conditions as well as the treatment of age-related macular degeneration, diabetic retinopathy, retinal vein occlusion, and other conditions. Dr Ip received his medical degree from New York University and completed his internship at Lenox Hill Hospital, both in New York, New York. He completed his residency at the University of Pittsburgh School of Medicine in Pennsylvania followed by a fellowship in vitreoretinal surgery at New England Eye Center, Tufts University, in Boston, Massachusetts.
Dr Ip’s research focuses on the design and conduct of clinical trials investigating treatments for diabetic retinopathy, age-related macular degeneration, and retinal venous occlusive disease. As Co-Director of the Fundus Photograph Reading Center, he has assisted with the collection, analysis, and dissemination of important secondary outcomes in ophthalmic clinical trials, such as the Eli Lilly trials for protein kinase C inhibitor for diabetic macular edema (MBBK), the transpupillary thermotherapy of occult subfoveal choroidal neovascular membranes in patients with age-related macular degeneration trial (TTT4CNV), the Control Delivery Systems trials evaluating intravitreal fluocinolone implants, and the Bausch & Lomb trials investigating fluocinolone acetonide intravitreal implant. As a clinical site investigator, he has served as the Principal Investigator on 10 clinical trials. He has also served as a protocol chair for the clinical trial conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema and as the National Principal Investigator for the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study. Dr Ip received an award from the National Eye Institute, National Institutes of Health in 2003 to conduct the SCORE study. He has authored more than 40 peer-reviewed articles, 19 book chapters, and more than 30 abstracts on these topics as well as given many national and international presentations. Dr Ip is also a reviewer for the following five journals: Ophthalmic Surgery and Lasers, Investigative Ophthalmology and Visual Science, American Journal of Ophthalmology, Retina, and Ophthalmology. He is currently an Associate Editor for Archives of Ophthalmology. In addition, he serves on a variety of committees in the American Academy of Ophthalmology, including the Ophthalmology Technology Assessment Committee and Curriculum Development Committee (COMPASS), and is a member of the Food and Drug Administration Panel on Orphan Drug Development. Dr Ip has been recognized with several honors, including the Achievement Award and the Leadership Development Program Award, both from the American Academy of Ophthalmology.
1. Summarize existing data on the available agents used to treat diabetic macular edema (DME) and age-related macular degeneration (AMD)
2. Discuss the evidence supporting current guideline recommendations for the diagnosis and treatment of DME and AMD
3. Describe the mechanisms of action of novel agents used in the treatment of DME and AMD

Instructions on How to Receive Credit
  • Participants must review the materials on accreditation information, target audience, learning objectives, and disclosure information.
  • Complete the 3 rounds of questions, post-test, and evaluation.
  • After passing the post-test, print out your electronic CME certificate.
  • In order to successfully complete this activity learners must achieve a minimum of 70% on the post-test.
Target Audience
The primary target audience for these activities is comprised of retinal specialists, although the education is appropriate for comprehensive ophthalmologists who manage and treat patients with DME and AMD.
This activity is supported by an educational grant from Genentech.

This activity is sponsored by the Institute for Continuing Healthcare Education.
Accreditation Statement
The Institute for Continuing Healthcare Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Institute designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)Physicians should only claim credit commensurate with the extent of their participation in the activity.
It is the policy of the Institute to ensure balance, independence, objectivity and scientific rigor in all its educational activities. All persons in control of content must disclose any significant financial interest or other relationships that may affect the content of this activity.

Relationships are abbreviated as follows: E, Educational Planning Committee; G, Grant/research support recipient; A, Advisor/review panel member/educational planning committee; C, Consultant/Independent Contractor; SS, Stock shareholder; SB, Speaker bureau; PE, Promotional Event Talks; H, Honoraria; O, Other.
David S. Boyer, MD, (Chair) has disclosed the following relevant financial relationships that have occurred within the past 12 months: Alcon, Allergan, Genentech, Neurotech/A; Alcon, Aerpio, Allegro, Allergan, Bausch & Lomb, Bayer, Genentech, KalVista, Neurotech, Novartis, Regeneron, Roche, ThromboGenics/C; Allergan, Genentech/SB; and Allegro/S.
Jeffrey S. Heier, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Acucela, Aerpio, Allergan, Bausch & Lomb, Bayer, Dutch Ophthalmic, Endo Optiks, Forsight, Genzyme. Heidelberg Engineering, Kanghong, Notal Vision, Ohr Pharmaceutical, Ophthotech, QLT, Regeneron, Roche, Sequenom, Thrombogenics, Vertex, Xcovery/C; and Aerpio, Alcon, Alimera, Allergan, Fovea, Genentech, Genzyme, GlaxoSmithKiline, Neovista, Notal Vision, Novartis, Ophthotech, Paloma, Regeneron/G.
Michael S. Ip, MD, has disclosed the following relevant financial relationships that have occurred within the past 12 months: Eye Technology, Ltd., Genentech, Neuronetics, Valeant/C; and Allergan/G.
Peer Reviewer
Christina Ohnsman, MD, has disclosed the following relevant financial relationships that have occured within the past 12 months: Alcon/A,SB.
Medical Writer
Tim Donald as disclosed that he has no relevant financial relationships specific to the subject matter of this activity that have occurred within the past 12 months.
Activity Development & Management Team
Cathy Pagano, CCMEP; Allison Muller, Pharm.D, D.ABAT;  Scott Kober, MBA, CCMEP; April Reynolds MS, ELS; Sandra Davidson; and Megan Small; are employees of the Institute and are collectively responsible for the planning, development, and management of this CME activity. These individuals have disclosed that they have had no relevant financial relation­ships specific to the subject matter of this activity that have occurred within the past 12 months.
Product Disclosure
This educational activity includes discussion of published and/or investigational uses of agents that are not indicated by the U.S. Food and Drug Administration. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

The educational content of this activity has been peer reviewed and validated to ensure that it is a fair and balanced representation of the topic, based on the best available evidence.Con
Supported Browsers:
Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash or Quicktime.
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

For additional technical support, please send an email to msmall@iche.edu.  
General Disclosure and Copyright Statement
The opinions expressed in this publication are those of the participating faculty and not those of the Institute for Continuing Healthcare Education (the Institute), Genentech, Inc., or any manufacturers of products mentioned herein.

This information is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a healthcare professional regarding diagnostic and treatment options of a specific patient's medical condition. In no event will the Institute be responsible for any decision made or action taken based upon the information provided in this activity.

Participants are encouraged to consult the package insert for all products for updated information and changes regarding indications, dosages, and contraindications. This recommendation is particularly important for new or infrequently used products.

Copyright 2014. Institute for Continuing Healthcare Education (the Institute). All rights reserved. No part of this publication may be reproduced or transmitted in any other form or by any means electronic or mechanical—without first obtaining written permission from the Institute.
The Institute reserves the right to cancel or modify the activity content, faculty, and activities if necessary.